Navigation Links
CuraGen to Present CR011-vcMMAE Data at ASCO
Date:5/28/2009

ragen.com following the presentations.

Conference Call Details and Dial-in Information

    Date:       Wednesday, June 3, 2009
    Time:       11:00 a.m. EDT
    Dial-in:    (877)-856-1956  (U.S. and Canada)
                (719)-325-4771  (international)

Webcast: Access available at http://www.curagen.com

About CR011-vcMMAE

CR011-vcMMAE is an antibody-drug conjugate (ADC) being developed by CuraGen that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CR011-vcMMAE targets and binds to GPNMB, a specific protein that is predominantly expressed on the surface of cancer cells, including melanoma, breast cancer and gliomas. Upon internalization into the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. CR011-vcMMAE is currently in two Phase II trials assessing the safety and efficacy in the treatment of melanoma and for the treatment of metastatic breast cancer, and in a Phase I trial to evaluate the safety and activity of alternate dosing schedules.

About Breast Cancer

Breast cancer is the most common cancer in women and a leading cause of death in the United States. According to the American Cancer Society, more than 180,000 women will be diagnosed with invasive breast cancer in 2009 with more than 40,000 deaths attributed to this disease. Despite recent advances in therapy, the median survival of patients with metastatic breast cancer is 2 to 3 years, while patients with "triple-nega
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... , Nov. 24, 2014  Marta Rendon, MD, founder of ... Boca Raton , FL and international key opinion leader in ... the United States to attend the ... Istanbul, Turkey . Here, at this gathering of over ... world renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... ,Oct. 19, 2011 Innocoll, Inc. announced it has ... Pharma in China for CollaGUARD surgical adhesion barrier for ... surgery.   Dr. Michael Myers, President and ... China is becoming an increasingly important and dynamic market ...
... YORK, Oct. 19, 2011 Reportlinker.com announces that ... its catalogue: Syncria (Type ... http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Forecasts to 2020 Summary ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:11/26/2014)... November 26, 2014 The family foundation ... to the Mesothelioma Applied Research Foundation (Meso Foundation), half ... Foundation’s Patient Travel Grant Program . The focus ... to create grant partnerships with organizations that can generate ... Mr. Schulze is the founder and chairman emeritus of ...
(Date:11/26/2014)... The American Anthropological Association (AAA) has ... of meetings and conferences. Suvarnakar will be responsible ... and conferences. , “I am pleased to ... Executive Director Ed Liebow. “She brings the Association ... was recognized in January as the 2013 Professional ...
(Date:11/26/2014)... For its December issue , ... Report on Blue Cross and Blue Shield Plans* interviewed ... varied strategies the two Blues plans are implementing in ... for sleep apnea, ranging from brick-and-mortar retail stores to ... to increased rates of a variety of serious disorders, ...
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... blood test for the efficient and swift detection of ... Medical Research Council National Institute for Medical Research// team ... further explained that the test watches out for biomarkers ... that is used for testing TB is for looking ...
... to the latest study by the Mayo clinic, injecting an ... biopsy.// ,The new study that is being presented ... of the American Urological Association, in San Diego, had found ... level of pain during their biopsy. It was explained that ...
... of Texas, Ann Richards marks the rapid increase in esophageal cancer ... diagnosed with esophageal cancer.// Only 16 % or around 2,200, of ... survive in 5 years. ,There has been a 6-fold annual ... 20 years, according to experts. Rise in obesity cases has been ...
... in the Friday’s issue of the British Medical Journal, calcium supplements ... later years.// ,According to the research, 90% of the ... Hence, it is expected that enhancing bone mass at an early ... ,The results of 19 studies, on about 2,900 kids ...
... drug that is being developed for multiple sclerosis might prove ... the experimental drug fingolimod might be effective in helping patients ... study that if in the larger and detailed studies could ... it could offer patients with MS the first effective treatment ...
... exercise has the potential to reduce the risk of colon ... US researchers says. //Lead researcher Dr. Anne McTiernan of Seattle’s ... women aged 40-75 years. ,WebMD reports that half the ... Neither group had any change in their diets. Men who ...
Cached Medicine News:Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2